Loading
companiesCompany
Triana Biomedicines
Triana Biomedicines designs molecular glues that make cancer cells destroy their own faulty proteins. Its first drug, TRI-611, removes the ALK fusion protein that drives a subset of lung cancers and has entered human trials.
Overview
Triana Biomedicines is a Lexington, Massachusetts company with a target-first molecular glue discovery platform that pairs disease targets with the most suitable of more than 600 E3 ubiquitin ligases. Its lead candidate, TRI-611, is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins to cereblon independently of the kinase active site, intended to overcome resistance, CNS metastases and tolerability limits of ALK inhibitors in ALK-positive non-small cell lung cancer; it has entered the clinic. A CCNE1 (cyclin E1) degrader programme targets CCNE1-amplified tumours and a subset of HR-positive/HER2-negative breast cancers. Triana launched in April 2022 with 110 million US dollars in total funding (seeded by RA Capital and Atlas Venture, Series A co-led by Lightspeed) and closed a 120 million US dollar Series B in December 2025 co-led by Ascenta Capital and Bessemer Venture Partners.
Headquarters
Lexington, MA, US
Scorecard
All companies#453of 1244 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Oversubscribed; co-led by Ascenta Capital and Bessemer Venture Partners; closed December 2025 | 2025 | $120M | trianabio.com |
| Series A · Launch announcement of 110 million US dollars total funding (seed from RA Capital and Atlas Venture plus Series A co-led by Lightspeed); the Series A portion alone is not itemised | 2022 | $110M | trianabio.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Founded
2019
Phase 2protein degrader
TRI-611 is an experimental protein degrader from TRIANA Biomedicines in phase 2 trials for non-small-cell lung cancer, aimed at ALK.
Notes
top- SEC Form D filings show 42.55 million US dollars sold by April 2022 and 120.06 million sold by December 2025, consistent with tranche-based funding of the announced totals. Founding year from the Form D year of incorporation.
Similar pages
- CompanyObsidian Therapeutics
Shares Logos Capital, Atlas Venture, RA Capital Management, Non-small-cell lung cancer.
- CompanyMariana Oncology
Shares Atlas Venture, RA Capital Management.
- CompanyPheon Therapeutics
Shares Lightspeed Venture Partners, Atlas Venture.
- CompanyAlpha-9 Oncology
- CompanyNucleix
- CompanyAdcendo
Shares Logos Capital, RA Capital Management.
- CompanyEnliven Therapeutics
- CompanyTango Therapeutics
Shares Logos Capital, RA Capital Management, Non-small-cell lung cancer.
cancers
fronts
technologies
targets
drugs
Phase 2protein degrader